New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
07:36 EDTCYTKCytokinetics presents analyses from Tirasemtiv clinical trials in ALS patients
Cytokinetics announced a platform presentation of pharmacokinetic data and pharmacokinetic/pharmacodynamic analyses from three previously-reported clinical trials of tirasemtiv in patients with amyotrophic lateral sclerosis, or ALS, at the 23rd International Symposium on ALS and Motor Neurone Diseases, or ALS/MND, in Chicago, IL. Tirasemtiv selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, which increases skeletal muscle force in response to neuronal input. In preclinical studies, this mechanism has been shown to delay the onset and reduce the degree of muscle fatigue. Tirasemtiv is currently being evaluated in BENEFIT-ALS, an international, double-blind, randomized, placebo- controlled, Phase IIb clinical trial designed to evaluate the safety, tolerability and potential efficacy of this novel drug candidate in patients with ALS.
News For CYTK From The Last 14 Days
Check below for free stories on CYTK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
14:33 EDTCYTKCytokinetics volatility elevated into trial data announcement
Cytokinetics May call option implied volatility is at 279, August is at 180, November is at 140; compared to its 26-week average of 158 according to Track Data, suggesting larger near term price movement into the tirasemtiv Phase IIb trial data likely to be announced at the American Academy of Neurology meeting in late April.
April 11, 2014
10:56 EDTCYTKOptions with increasing implied volatility: CYTK VJET DATA GRPN CTRP
April 10, 2014
11:23 EDTCYTKOptions with increasing implied volatility: CYTK BX
Subscribe for More Information
April 9, 2014
11:45 EDTCYTKOptions with increasing implied volatility: CYTK NSR NOW ETFC PBR
08:30 EDTCYTKSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Cytokinetics' (CYTK) Tirasemtiv for treatment of Amyotrophic Lateral Sclerosis (ALS) on an Analyst/Industry conference call to be held on April 9 at 11 am.
April 8, 2014
11:22 EDTCYTKOptions with increasing implied volatility: CYTK NSR NOW ETFC SPLK
Subscribe for More Information
09:08 EDTCYTKCytokinetics volatility elevated into trial data announcement
Subscribe for More Information
April 7, 2014
17:02 EDTCYTKSAC Capital reports 5.5% passive stake in Cytokinetics
11:37 EDTCYTKOptions with increasing implied volatility: CYTK NSR NOW ETFC LF
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use